EA202190357A3 - NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF SEVERAL TYPES OF CANCER - Google Patents
NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF SEVERAL TYPES OF CANCERInfo
- Publication number
- EA202190357A3 EA202190357A3 EA202190357A EA202190357A EA202190357A3 EA 202190357 A3 EA202190357 A3 EA 202190357A3 EA 202190357 A EA202190357 A EA 202190357A EA 202190357 A EA202190357 A EA 202190357A EA 202190357 A3 EA202190357 A3 EA 202190357A3
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- peptides
- cells
- present
- tumor
- immunotherapy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Настоящее изобретение относится к пептидам, белкам, нуклеиновым кислотам и клеткам для применения в иммунотерапевтических методах. В частности, настоящее изобретение относится к иммунотерапии рака. Настоящее изобретение относится далее к опухолеассоциированным пептидным эпитопам Т-клеток, в отдельности или в комбинации с другими опухолеассоциированными пептидами, которые могут, например, служить в качестве активных фармацевтических ингредиентов вакцинных композиций, стимулирующих противоопухолевые иммунные ответы, или стимулировать Т-клетки ex vivo с их перенесением в организм пациента. Пептиды, связанные с молекулами главного комплекса гистосовместимости (MHC), или пептиды в отдельности могут быть также мишенями антител, растворимых Т-клеточных рецепторов и других связывающих молекул.The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to cancer immunotherapy. The present invention further relates to tumor-associated peptide epitopes of T cells, alone or in combination with other tumor-associated peptides, which can, for example, serve as active pharmaceutical ingredients in vaccine compositions that stimulate anti-tumor immune responses, or stimulate T cells ex vivo with their transfer to the patient's body. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides alone, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562266233P | 2015-12-11 | 2015-12-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA202190357A2 EA202190357A2 (en) | 2021-06-30 |
| EA202190357A3 true EA202190357A3 (en) | 2021-09-30 |
Family
ID=61768589
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190357A EA202190357A3 (en) | 2015-12-11 | 2016-12-05 | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF SEVERAL TYPES OF CANCER |
| EA202092502A EA202092502A3 (en) | 2015-12-11 | 2016-12-05 | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF SEVERAL TYPES OF CANCER |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202092502A EA202092502A3 (en) | 2015-12-11 | 2016-12-05 | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF SEVERAL TYPES OF CANCER |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR107025A1 (en) |
| EA (2) | EA202190357A3 (en) |
-
2016
- 2016-12-05 EA EA202190357A patent/EA202190357A3/en unknown
- 2016-12-05 EA EA202092502A patent/EA202092502A3/en unknown
- 2016-12-07 AR ARP160103771A patent/AR107025A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA202092502A2 (en) | 2021-02-26 |
| EA202092502A3 (en) | 2021-06-30 |
| EA202190357A2 (en) | 2021-06-30 |
| AR107025A1 (en) | 2018-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201992664A3 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF OVARIAN CANCER AND OTHER TYPES OF CANCER | |
| EA202191027A2 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF SEVERAL TUMORS | |
| EA201891116A1 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR THE USE OF SEVERAL CANCER TYPES IN IMMUNOTHERAPY | |
| EA201891465A1 (en) | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR APPLICATION IN BREAST CANCER IMMUNOTHERAPY AND OTHER CANCER TYPES | |
| EA201890635A1 (en) | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR APPLICATION IN IMMUNOTHERAPY OF SMALL CELLS OF LUNG AND OTHER CANCER SPECIES | |
| EA201891638A1 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN NHL IMMUNOTHERAPY AND OTHER CANCER TYPES | |
| EA201891074A1 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR APPLICATION IN CLL IMMUNOTHERAPY AND OTHER CANCER TYPES | |
| EA201992416A1 (en) | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR APPLICATION IN IMMUNOTHERAPY OF LEUKOSIS AND OTHER TYPES OF CANCER | |
| EA201891994A1 (en) | Uterus Cancer Treatment | |
| EA202091754A1 (en) | PEPTIDES AND COMBINATIONS OF PEPTIDES OF NON-CANONIC ORIGIN FOR USE IN IMMUNOTHERAPY OF DIFFERENT TYPES OF CANCER | |
| EA201892159A1 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR THE USE OF AML AND OTHER CANCER IN IMMUNOTHERAPY | |
| EA202190186A1 (en) | PEPTIDES, COMBINATIONS OF PEPTIDES AND CELL-BASED MEDICINES FOR USE IN IMMUNOTHERAPY OF BLADDER CANCER AND OTHER TYPES OF CANCER | |
| EA202092502A3 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF SEVERAL TYPES OF CANCER | |
| EA201992417A1 (en) | PEPTIDES AND THEIR COMBINATIONS FOR THE APPLICATION OF CANCER DISEASES IN IMMUNOTHERAPY | |
| EA202091988A1 (en) | PEPTIDES FOR USE IN IMMUNOTHERAPY OF CANCER | |
| EA202190465A2 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY NHL AND OTHER TYPES OF CANCER | |
| EA202190241A1 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF CLL AND OTHER TYPES OF CANCER | |
| EA202190898A2 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF PANCREAS CANCER AND OTHER TYPES OF CANCER | |
| EA202191013A2 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AND METHODS FOR OBTAINING FRAMEWORK FOR USE IN TREATMENT OF PANCREAS CANCER AND OTHER TYPES OF CANCER | |
| EA202091878A3 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NON-SMALL CELL LUNG CANCER (NSCLC) AND OTHER TYPES OF CANCER | |
| EA202092543A2 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES AND FRAMEWORK FOR USE IN IMMUNOTHERAPY OF RENAL CELL CARCINOMA (RCC) AND OTHER TYPES OF CANCER |